title: Pharmacological characterization of GABAA receptors in taurine-fed mice.
abstract: BACKGROUND
  Taurine is one of the most abundant free amino acids especially in excitable tissues, with wide physiological actions. Chronic supplementation of taurine in drinking water to mice increases brain excitability mainly through alterations in the inhibitory GABAergic system. These changes include elevated expression level of glutamic acid decarboxylase (GAD) and increased levels of GABA. Additionally we reported that GABAA receptors were down regulated with chronic administration of taurine. Here, we investigated pharmacologically the functional significance of decreased / or change in subunit composition of the GABAA receptors by determining the threshold for picrotoxin-induced seizures. Picrotoxin, an antagonist of GABAA receptors that blocks the channels while in the open state, binds within the pore of the channel between the beta2 and beta3 subunits. These are the same subunits to which GABA and presumably taurine binds.
  
  
  METHODS
  Two-month-old male FVB/NJ mice were subcutaneously injected with picrotoxin (5 mg kg-1) and observed for a) latency until seizures began, b) duration of seizures, and c) frequency of seizures. For taurine treatment, mice were either fed taurine in drinking water (0.05%) or injected (43 mg/kg) 15 min prior to picrotoxin injection.
  
  
  RESULTS
  We found that taurine-fed mice are resistant to picrotoxin-induced seizures when compared to age-matched controls, as measured by increased latency to seizure, decreased occurrence of seizures and reduced mortality rate. In the picrotoxin-treated animals, latency and duration were significantly shorter than in taurine-treated animas. Injection of taurine 15 min before picrotoxin significantly delayed seizure onset, as did chronic administration of taurine in the diet. Further, taurine treatment significantly increased survival rates compared to the picrotoxin-treated mice.
  
  
  CONCLUSIONS
  We suggest that the elevated threshold for picrotoxin-induced seizures in taurine-fed mice is due to the reduced binding sites available for picrotoxin binding due to the reduced expression of the beta subunits of the GABAA receptor. The delayed effects of picrotoxin after acute taurine injection may indicate that the two molecules are competing for the same binding site on the GABAA receptor. Thus, taurine-fed mice have a functional alteration in the GABAergic system. These include: increased GAD expression, increased GABA levels, and changes in subunit composition of the GABAA receptors. Such a finding is relevant in conditions where agonists of GABAA receptors, such as anesthetics, are administered.
authors.affiliation: Department of Biology, College of Staten Island, 2800 Victory Blvd, Staten Island, NY 10314, USA. William.Lamoreaux@csi.cuny.edu
authors.forename: William J
authors.initials: WJ
authors.lastname: L'Amoreaux
authors.forename: Alexandra
authors.initials: A
authors.lastname: Marsillo
authors.forename: Abdeslem
authors.initials: A
authors.lastname: El Idrissi
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D018756:GABA Antagonists / Q000494:pharmacology; D005968:Glutamate Decarboxylase / Q000378:metabolism; D008297:Male; D051379:Mice; D010852:Picrotoxin / Q000494:pharmacology; D011963:Receptors, GABA-A / Q000378:metabolism*; D012640:Seizures / Q000139:chemically induced; D013654:Taurine / Q000008:administration & dosage*; D005680:gamma-Aminobutyric Acid / Q000378:metabolism
chemical_list: D018756:GABA Antagonists; D005968:Glutamate Decarboxylase; D010852:Picrotoxin; D011963:Receptors, GABA-A; D013654:Taurine; D005680:gamma-Aminobutyric Acid
references.citation: Expert Rev Neurother. 2006 Apr;6(4):575-89
references.pmid: 16623656
references.citation: J Neurochem. 1983 Aug;41(2):524-30
references.pmid: 6875551
references.citation: J Neurochem. 1993 Feb;60(2):395-407
references.pmid: 8419527
references.citation: Physiol Rev. 1993 Jan;73(1):119-47
references.pmid: 8419963
references.citation: Adv Exp Med Biol. 1992;315:263-8
references.pmid: 1324594
references.citation: Trends Pharmacol Sci. 1998 Dec;19(12):500-5
references.pmid: 9871412
references.citation: Br J Pharmacol. 2003 Mar;138(6):1163-71
references.pmid: 12684273
references.citation: J Pharmacol Exp Ther. 1967 Sep;157(3):546-54
references.pmid: 6048015
references.citation: FASEB J. 2004 Mar;18(3):511-8
references.pmid: 15003996
references.citation: Prog Neurobiol. 2000 Oct;62(2):113-34
references.pmid: 10828380
references.citation: Can J Physiol Pharmacol. 1968 Sep;46(5):803-4
references.pmid: 5681539
references.citation: Adv Exp Med Biol. 2009;643:199-206
references.pmid: 19239150
references.citation: J Neurochem. 2003 Aug;86(4):879-87
references.pmid: 12887686
references.citation: Dev Biol. 1992 Sep;153(1):158-64
references.pmid: 1516745
references.citation: Proc Natl Acad Sci U S A. 1982 May;79(10):3355-9
references.pmid: 6124970
references.citation: Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5185-90
references.pmid: 16537435
references.citation: Nature. 1962 Jan 20;193:301-2
references.pmid: 13875057
references.citation: Neuroscience. 2008 Oct 15;156(3):693-9
references.pmid: 18727952
references.citation: Exp Neurol. 2000 Feb;161(2):714-23
references.pmid: 10686090
references.citation: Prog Neurobiol. 1989;32(6):471-533
references.pmid: 2664881
references.citation: Neuroscience. 1985 Feb;14(2):375-403
references.pmid: 2859548
references.citation: J Neurochem. 1988 Sep;51(3):740-5
references.pmid: 3411323
references.citation: Comp Biochem Physiol B. 1973 Aug 15;45(4):741-8
references.pmid: 4737979
references.citation: Amino Acids. 2000;19(3-4):527-46
references.pmid: 11140357
references.citation: Brain Res. 1985 Jul 15;338(2):289-95
references.pmid: 4027598
references.citation: Neuropharmacology. 1995 Dec;34(12):1607-13
references.pmid: 8788958
references.citation: J Comp Neurol. 1999 Sep 27;412(3):488-505
references.pmid: 10441235
references.citation: Acta Neurochir Suppl (Wien). 1994;60:571-3
references.pmid: 7976653
references.citation: J Neurosci. 1998 Aug 1;18(15):5938-47
references.pmid: 9671680
references.citation: Dev Med Child Neurol. 1993 Mar;35(3):277
references.pmid: 8462764
references.citation: Synapse. 1997 Oct;27(2):122-32
references.pmid: 9266773
references.citation: Adv Exp Med Biol. 2000;483:213-8
references.pmid: 11787600
references.citation: Adv Exp Med Biol. 1998;442:329-37
references.pmid: 9635048
references.citation: Neurochem Res. 2004 Jan;29(1):189-97
references.pmid: 14992278
references.citation: Adv Exp Med Biol. 2003;526:515-25
references.pmid: 12908638
references.citation: Neurosci Lett. 2008 May 2;436(1):19-22
references.pmid: 18375059